An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Treprostinil (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Adverse reactions
- Acronyms TETON-OLE
- Sponsors United Therapeutics Corporation
- 27 Aug 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2026.
- 22 May 2024 Trial design presented at the 120th International Conference of the American Thoracic Society.
- 24 Aug 2022 According to a United Therapeutics Corporation media release, additional details of the trial will be presented at the European Respiratory Society International Congress 2022.